Dow Jones

39,118.86

-0.12%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OCEA

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
05/06/2024	06:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024	NASDAQ:OCEA	Ocean Biomedical Inc
30/05/2024	06:44	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q	NASDAQ:OCEA	Ocean Biomedical Inc
16/05/2024	07:01	GlobeNewswire Inc.	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease	NASDAQ:OCEA	Ocean Biomedical Inc
24/04/2024	15:51	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	NASDAQ:OCEA	Ocean Biomedical Inc
28/03/2024	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL	NASDAQ:OCEA	Ocean Biomedical Inc
08/03/2024	16:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCEA	Ocean Biomedical Inc
29/02/2024	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting	NASDAQ:OCEA	Ocean Biomedical Inc
13/02/2024	17:43	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OCEA	Ocean Biomedical Inc
05/12/2023	07:15	GlobeNewswire Inc.	Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody	NASDAQ:OCEA	Ocean Biomedical Inc
15/11/2023	05:20	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:OCEA	Ocean Biomedical Inc
14/11/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	NASDAQ:OCEA	Ocean Biomedical Inc
26/10/2023	04:30	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection	NASDAQ:OCEA	Ocean Biomedical Inc
26/10/2023	04:30	PR Newswire (US)	Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection	NASDAQ:OCEA	Ocean Biomedical Inc
24/10/2023	05:30	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis	NASDAQ:OCEA	Ocean Biomedical Inc
17/10/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics	NASDAQ:OCEA	Ocean Biomedical Inc
12/10/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide	NASDAQ:OCEA	Ocean Biomedical Inc
12/10/2023	07:01	PR Newswire (US)	Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide	NASDAQ:OCEA	Ocean Biomedical Inc
04/10/2023	15:56	GlobeNewswire Inc.	Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund	NASDAQ:OCEA	Ocean Biomedical Inc
04/10/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million	NASDAQ:OCEA	Ocean Biomedical Inc
03/10/2023	13:30	GlobeNewswire Inc.	Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner	NASDAQ:OCEA	Ocean Biomedical Inc
03/10/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	NASDAQ:OCEA	Ocean Biomedical Inc
14/09/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.	NASDAQ:OCEA	Ocean Biomedical Inc
29/08/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.	NASDAQ:OCEA	Ocean Biomedical Inc
16/08/2023	16:10	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:OCEA	Ocean Biomedical Inc
10/08/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers	NASDAQ:OCEA	Ocean Biomedical Inc
09/08/2023	07:31	GlobeNewswire Inc.	Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.	NASDAQ:OCEA	Ocean Biomedical Inc
04/08/2023	16:15	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:OCEA	Ocean Biomedical Inc
01/08/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day	NASDAQ:OCEA	Ocean Biomedical Inc
24/07/2023	16:00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:OCEA	Ocean Biomedical Inc
11/07/2023	07:01	GlobeNewswire Inc.	Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges	NASDAQ:OCEA	Ocean Biomedical Inc